UBS Maintains Buy on AnaptysBio, Raises Price Target to $76

Benzinga Newsdesk www.benzinga.com Positive 72.3%

Neg 0% Neu 0% Pos 72.3%

UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $60 to $76.

Comments

No comments yet. Be the first!